• 1
    Bray F, Loos AH, McCarron P, et al. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev 2005;14:67786.
  • 2
    Gustafsson L, Ponten J, Zack M, et al. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 1997;8:75563.
  • 3
    Mahlck CG, Jonsson H, Lenner P. Pap smear screening and changes in cervical cancer mortality in Sweden. Int J Gynaecol Obstet 1994;44:26772.
  • 4
    Andrae B, Kemetli L, Sparen P, et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst 2008;100:6229.
  • 5
    Lindqvist PG, Hellsten C, Rippe A. Screening history of women in Malmo with invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol 2008;137:7783.
  • 6
    Broberg G, Jonasson JM, Ellis J, et al. Increasing participation in cervical cancer screening: telephone contact with long-term non-attendees in Sweden. Results from RACOMIP, a randomized controlled trial. Int J Cancer 2013;133:16471.
  • 7
    Waller J, Bartoszek M, Marlow L, et al. Barriers to cervical cancer screening attendance in England: a population-based survey. J Med Screen 2009;16:199204.
  • 8
    Oscarsson MG, Benzein EG, Wijma BE. Reasons for non-attendance at cervical screening as reported by non-attendees in Sweden. J Psychosom Obstet Gynaecol 2008;29:2331.
  • 9
    Eaker S, Adami HO, Sparen P. Reasons women do not attend screening for cervical cancer: a population-based study in Sweden. Prev Med 2001;32:48291.
  • 10
    Segnan N, Senore C, Giordano L, et al. Promoting participation in a population screening program for breast and cervical cancer: a randomized trial of different invitation strategies. Tumori 1998;84:34853.
  • 11
    Morrell S, Taylor R, Zeckendorf S, et al. How much does a reminder letter increase cervical screening among under-screened women in NSW? Aust N Z J Public Health 2005;29:7884.
  • 12
    Eaker S, Adami HO, Granath F, et al. A large population-based randomized controlled trial to increase attendance at screening for cervical cancer. Cancer Epidemiol Biomarkers Prev 2004;13:34654.
  • 13
    Gok M, Heideman DA, van Kemenade FJ, et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ 2010;340:c1040.
  • 14
    Virtanen A, Anttila A, Luostarinen T, et al. Self-sampling versus reminder letter: effects on cervical cancer screening attendance and coverage in Finland. Int J Cancer 2010;128:26817.
  • 15
    Virtanen A, Nieminen P, Luostarinen T, et al. Self-sample HPV tests as an intervention for nonattendees of cervical cancer screening in Finland: a randomized trial. Cancer Epidemiol Biomarkers Prev 2011;20:19609.
  • 16
    Szarewski A, Cadman L, Mesher D, et al. HPV self-sampling as an alternative strategy in non-attenders for cervical screening—a randomised controlled trial. Br J Cancer 2011;104:91520.
  • 17
    Bais AG, van Kemenade FJ, Berkhof J, et al. Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. Int J Cancer 2007;120:150510.
  • 18
    Sanner K, Wikstrom I, Strand A, et al. Self-sampling of the vaginal fluid at home combined with high-risk HPV testing. Br J Cancer 2009;101:8714.
  • 19
    Wikstrom I, Lindell M, Sanner K, et al. Self-sampling and HPV testing or ordinary Pap-smear in women not regularly attending screening: a randomised study. Br J Cancer 2011;105:3379.
  • 20
    Gok M, van Kemenade FJ, Heideman DA, et al. Experience with high-risk human papillomavirus testing on vaginal brush-based self-samples of non-attendees of the cervical screening program. Int J Cancer 2012;130:112835.
  • 21
    Szarewski A, Cadman L, Mallett S, et al. Human papillomavirus testing by self-sampling: assessment of accuracy in an unsupervised clinical setting. J Med Screen 2007;14:3442.
  • 22
    Snijders PJ, Verhoef VM, Arbyn M, et al. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer 2013;132:222336.
  • 23
    Sammanställning av några kvalitetsdata 2010 gällande cervixcancerprevention i Västra Sverige [Compilation of quality data from 2010 concerning prevention of cervical cancer in West Sweden]. (in Swedish). Regionalt Cancercentrum Väst, 2011.
  • 24
    Socialstyrelsen. Gynekologisk cellprovskontroll. Förslag till ett screeningprogram 1998 [Guidelines for cervical screening] (in Swedish) SoS report 1998:15 Stockholm: National Board of Health and Welfare, 1998.
  • 25
    Barken SS, Rebolj M, Andersen ES, et al. Frequency of cervical intraepithelial neoplasia treatment in a well-screened population. Int J Cancer 2012;130:243844.
  • 26
    Schultz K, Altman D, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.
  • 27
    Giorgi Rossi P, Marsili LM, Camilloni L, et al. The effect of self-sampled HPV testing on participation to cervical cancer screening in Italy: a randomised controlled trial (ISRCTN96071600). Br J Cancer 2011;104:24854.
  • 28
    Socialstyrelsen. Background to a vaccination programme for the human papilloma virus in Sweden 2007 Stockholm: National Board of Health and Welfare, 2008.
  • 29
    Andrae B, Andersson TM, Lambert PC, et al. Screening and cervical cancer cure: population based cohort study. BMJ 2012;344:e900.